Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 20, 2023

Eflornithine Maintenance After Consolidation Immunotherapy in Patients With High-Risk Neuroblastoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons
J. Clin. Oncol 2023 Oct 26;[EPub Ahead of Print], J Oesterheld, W Ferguson, JM Kraveka, G Bergendahl, T Clinch, E Lorenzi, D Berry, RK Wada, MS Isakoff, DE Eslin, VI Brown, W Roberts, P Zage, VL Harrod, DS Mitchell, D Hanson, GL Saulnier Sholler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading